GlassScriptPhysician profile
Robert K Byram
NPI 1356528616
$9,788.47
in general payments reported to CMS, 2019-2025
48 companies · $1,478 in 2025
The $1,478 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $152 · 2022: $1,878 · 2023: $4,523 · 2024: $1,757 · 2025: $1,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,133 · Consulting Fee: $1,155 · Education: $256 · Travel and Lodging: $214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,132.58 |
| Consulting Fee | $1,155.00 |
| Education | $256.49 |
| Travel and Lodging | $213.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $2,860.29 | 2021-2025 | Jakafi, Niktimvo, Monjuvi |
| Sobi, INC | $539.79 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $520.73 | 2022-2025 | |
| Astellas Pharma US INC | $415.46 | 2022-2025 | Xospata, Cresemba, Vyloy |
| Celgene Corporation | $395.68 | 2022-2025 | Reblozyl, Pomalyst, Onureg |
| Genzyme Corporation | $370.37 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $341.28 | 2022-2023 | |
| Glaxosmithkline, LLC. | $336.33 | 2022-2025 | Ojjaara |
| Janssen Biotech, INC. | $330.37 | 2022-2025 | Imbruvica, Tecvayli, Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $320.79 | 2022-2023 | |
| Eisai INC. | $273.73 | 2022-2023 | |
| Karyopharm Therapeutics INC. | $261.55 | 2023-2024 | Xpovio |
| Takeda Pharmaceuticals U.S.A., INC. | $246.61 | 2022-2024 | Ninlaro, Livtencity |
| Merck Sharp & Dohme LLC | $211.06 | 2022-2024 | Keytruda, Lynparza, Prevymis |
| Rigel Pharmaceuticals, INC. | $197.50 | 2023-2024 | Tavalisse, Rezlidhia |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $171.77 | 2023 | Kyprolis, Nplate, Xgeva |
| Alexion Pharmaceuticals, INC. | $161.80 | 2023-2025 | Ultomiris |
| Pharmaessentia USA Corporation | $160.00 | 2023-2024 | Besremi |
| Adc Therapeutics America, INC. | $151.27 | 2022-2024 | |
| Novo Nordisk INC | $136.79 | 2025 | Alhemo |
| Bayer Healthcare Pharmaceuticals INC. | $121.32 | 2022-2023 | |
| Btg International INC. | $97.65 | 2022 | |
| Taiho Oncology, INC. | $97.06 | 2022-2025 | |
| Abbvie INC. | $94.40 | 2023-2025 | |
| Cti Biopharma Corp. | $83.48 | 2023 | Vonjo |
| Sanofi-Aventis U.S. LLC | $80.17 | 2022-2024 | |
| Genentech USA, INC. | $77.15 | 2022-2025 | Polivy, Columvi, Lunsumio |
| Csl Behring | $74.77 | 2025 | Hemgenix |
| Beigene USA, INC. | $68.35 | 2022-2025 | Brukinsa |
| Adaptive Biotechnologies Corporation | $64.71 | 2023-2024 | Clonoseq |
| Apellis Pharmaceuticals, INC. | $62.44 | 2022-2024 | Empaveli |
| Pfizer INC. | $61.09 | 2021-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $46.93 | 2023 | Epkinly, Imbruvica |
| Acrotech Biopharma INC. | $43.93 | 2022-2023 | Beleodaq |
| Kyowa Kirin, INC. | $42.73 | 2023 | Poteligeo |
| Daiichi Sankyo INC. | $36.48 | 2022-2023 | Enhertu |
| Servier Pharmaceuticals LLC | $32.10 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $25.52 | 2024 | Sylvant |
| Syndax Pharmaceuticals, INC. | $24.21 | 2025 | |
| Chiesi USA, INC. | $23.55 | 2025 | Ferriprox |
| Epizyme, INC. | $20.83 | 2021 | |
| Emd Serono, INC. | $17.22 | 2023 | Bavencio |
| Regeneron Healthcare Solutions, INC. | $16.82 | 2025 | Libtayo |
| Morphosys, US INC. | $16.09 | 2023 | Monjuvi |
| Bausch Health US, LLC | $14.48 | 2021 | |
| Gilead Sciences, INC. | $14.39 | 2023 | |
| Paratek Pharmaceuticals, INC. | $14.02 | 2024 | Nuzyra |
| Blueprint Medicines Corporation | $13.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Byram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.